1
|
Glyn T, Oar A, Vatandoust S, Heriot A, Jain A. Rectal cancer treatment: an embarrassment of riches? ANZ J Surg 2023; 93:2293-2294. [PMID: 37503692 DOI: 10.1111/ans.18634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2023] [Revised: 07/10/2023] [Accepted: 07/19/2023] [Indexed: 07/29/2023]
Affiliation(s)
- Tamara Glyn
- Department of Surgery and Critical Care, University of Otago Christchurch, Christchurch, New Zealand
- Department of Surgery, Te Whatu Ora Waitaha, Waitaha, New Zealand
| | - Andrew Oar
- Icon Cancer Centre, Gold Coast University Hospital, Gold Coast, Queensland, Australia
| | - Sina Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
| | - Alexander Heriot
- Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Ankit Jain
- Department of Medical Oncology, The Canberra Hospital, Canberra, Australian Capital Territory, Australia
- ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia
| |
Collapse
|
2
|
Jain A, Gormly KL, Glyn T, Sammour T, Koay EJ, Oar A, Jameson MB, Smyth EC, Vatandoust S. Management of rectal cancer in the era of total neoadjuvant therapy and watch and wait: A multidisciplinary team discussion at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting 2022. Asia Pac J Clin Oncol 2023. [PMID: 37340953 DOI: 10.1111/ajco.13974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Accepted: 06/06/2023] [Indexed: 06/22/2023]
Abstract
Rectal cancer is a common malignancy. The management of rectal cancer has recently evolved and has undergone a paradigm shift with the advent of treatment approaches such as total neoadjuvant therapy and the watch-and-wait approach. However, despite the recently available evidence, there is no consensus on the optimal management approach in the setting of locally advanced rectal cancer. To address some of the controversies, a joint multidisciplinary panel discussion was conducted at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting in November 2022. Members from different subspecialties formed two panels and discussed three clinical cases in a debate format. Each case represented some of the complex issues faced by clinicians in this setting. The discussion is now presented in this manuscript, which depicts the different available management approaches and reiterates the importance of a multidisciplinary approach.
Collapse
Affiliation(s)
- Ankit Jain
- Department of Medical Oncology, The Canberra Hospital, Garran, Australian Capital Territory, Australia
- ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Kirsten L Gormly
- Jones Radiology, Eastwood, South Australia, Australia
- The University of Adelaide, Adelaide, South Australia, Australia
| | - Tamara Glyn
- Department of Surgery and Critical Care, University of Otago, Christchurch, New Zealand
| | - Tarik Sammour
- School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
- Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Eugene J Koay
- Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Andrew Oar
- Icon Cancer Centre, Gold Coast University Hospital, Southport, Queensland, Australia
| | - Michael B Jameson
- Regional Cancer Centre, Waikato Hospital, Hamilton, New Zealand
- Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland, Hamilton, New Zealand
| | - Elizabeth C Smyth
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Sina Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia
- College of Medicine and Public Health, Flinders University, Bedford Park, Australia
| |
Collapse
|
3
|
Luigjes-Huizer YL, Tauber NM, Humphris G, Kasparian NA, Lam WWT, Lebel S, Simard S, Smith AB, Zachariae R, Afiyanti Y, Bell KJL, Custers JAE, de Wit NJ, Fisher PL, Galica J, Garland SN, Helsper CW, Jeppesen MM, Liu J, Mititelu R, Monninkhof EM, Russell L, Savard J, Speckens AEM, van Helmondt SJ, Vatandoust S, Zdenkowski N, van der Lee ML. What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psychooncology 2022; 31:879-892. [PMID: 35388525 PMCID: PMC9321869 DOI: 10.1002/pon.5921] [Citation(s) in RCA: 70] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 02/14/2022] [Accepted: 03/09/2022] [Indexed: 12/20/2022]
Abstract
Objective Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI‐SF). We also report on associations between FCR and clinical and demographic characteristics. Methods This is a systematic review and individual participant data (IPD) meta‐analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI‐SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Results IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI‐SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis. Conclusions FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR. The protocol was prospectively registered (PROSPERO CRD42020142185).
Collapse
Affiliation(s)
- Yvonne L Luigjes-Huizer
- Helen Dowling Institute, Bilthoven, The Netherlands.,Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Nina M Tauber
- Unit for Psychooncology and Health Psychology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
| | - Gerry Humphris
- School of Medicine, University of St Andrews, St Andrews, UK
| | - Nadine A Kasparian
- Cincinnati Children's Center for Heart Disease and Mental Health, Heart Institute and the Division of Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Wendy W T Lam
- Division of Behavioural Sciences, School of Public Health, and LKS Faculty of Medicine Jockey Club Institute of Cancer Care, University of Hong Kong, Hong Kong, China
| | - Sophie Lebel
- Faculty of Social Sciences, University of Ottawa, Ottawa, Ontario, Canada
| | - Sébastien Simard
- Université du Québec à Chicoutimi (UQAC), Centre Intersectoriel en santé durable, Québec, Québec, Canada
| | - Allan Ben Smith
- Ingham Institute for Applied Medical Research and South West Sydney Clinical Campuses, UNSW, Sydney, New South Wales, Australia
| | - Robert Zachariae
- Unit for Psychooncology and Health Psychology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
| | - Yati Afiyanti
- Department of Maternity and Women Health, Faculty of Nursing, Universitas Indonesia, Depok, Indonesia
| | - Katy J L Bell
- Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - José A E Custers
- Department of Medical Psychology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands
| | - Niek J de Wit
- Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Peter L Fisher
- Department of Psychological Sciences, University of Liverpool, Liverpool, UK
| | - Jacqueline Galica
- Division of Cancer Care and Epidemiology, Queen's University, Kingston, Ontario, Canada
| | - Sheila N Garland
- Department of Psychology, Faculty of Science, Memorial University, St. John's, Newfoundland, Canada
| | - Charles W Helsper
- Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Mette M Jeppesen
- Department of Gynaecology and Obstetrics, Odense University Hospital, Odense, Denmark
| | - Jianlin Liu
- Research Division, Institute of Mental Health, Singapore, Singapore
| | - Roxana Mititelu
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Evelyn M Monninkhof
- Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Lahiru Russell
- Centre for Quality and Patient Safety Research & Institute for Health Transformation, School of Nursing and Midwifery, Deakin University, Geelong, Victoria, Australia.,Centre for Quality and Patient Safety Research - Eastern Health Partnership, Box Hill, Victoria, Australia
| | - Josée Savard
- School of Psychology, Université Laval, CHU de Québec-Université Laval Research Center, Université Laval Cancer Research Centre, Quebec, Québec, Canada
| | - Anne E M Speckens
- Department of Psychiatry, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Sanne J van Helmondt
- Helen Dowling Institute, Bilthoven, The Netherlands.,Department of Medical and Clinical Psychology, Center of Research on Psychology in Somatic diseases, Tilburg University, Tilburg, The Netherlands
| | - Sina Vatandoust
- College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia
| | - Nicholas Zdenkowski
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
| | - Marije L van der Lee
- Helen Dowling Institute, Bilthoven, The Netherlands.,Department of Medical and Clinical Psychology, Center of Research on Psychology in Somatic diseases, Tilburg University, Tilburg, The Netherlands
| |
Collapse
|
4
|
Vatandoust S, Wattchow D, Sposato L, Michael MZ, Leung J, Gormly K, Chen G, Symonds EL, Tie J, Papanicolas LE, Woods S, Gebski V, Mead K, Kuruni A, Karapetis CS. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. BMC Cancer 2022; 22:222. [PMID: 35232427 PMCID: PMC8887187 DOI: 10.1186/s12885-022-09304-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 02/16/2022] [Indexed: 11/12/2022] Open
Abstract
Background Rectal Cancer is a common malignancy. The current treatment approach for patients with locally advanced rectal cancer involves neoadjuvant chemoradiotherapy followed by surgical resection of the rectum. The resection can lead to complications and long-term consequences. A clinical complete response is observed in some patients after chemoradiotherapy. A number of recent studies have shown that patients can be observed safely after completing chemoradiotherapy (without surgery), provided clinical complete response has been achieved. In this approach, resection is reserved for cases of regrowth. This is called the watch and wait approach. This approach potentially avoids unnecessary surgical resection of the rectum and the resulting complications. In this study, we will prospectively investigate this approach. Methods Adult patients with a diagnosis of rectal cancer planned to receive neoadjuvant long course chemoradiotherapy (± subsequent combination chemotherapy) will be consented into the study prior to commencing treatment. After completing the chemoradiotherapy (± subsequent combination chemotherapy), based on the clinical response, subjects will be allocated to one of the following arms: subjects who achieved a clinical complete response will be allocated to the watch and wait arm and others to the standard management arm (which includes resection). The aim of the study is to determine the rate of local failure and other safety and efficacy outcomes in the watch and wait arm. Patient reported outcome measures and the use of biomarkers as part of the clinical monitoring will be studied in both arms of the study. Discussion This study will prospectively investigate the safety of the watch and wait approach. We will investigate predictive biomarkers (molecular biomarkers and imaging biomarkers) and patient reported outcome measures in the study population and the cost effectiveness of the watch and wait approach. This study will also help evaluate a defined monitoring schedule for patients managed with the watch and wait approach. This protocol covers the first two years of follow up, we are planning a subsequent study which covers year 3–5 follow up for the study population. Trial registration. Name of the registry: Australia and New Zealand Clinical Trials Registry (ANZCTR). Trial registration number: Trial ID: ACTRN12619000207112 Registered 13 February 2019,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376810 Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09304-x.
Collapse
Affiliation(s)
- Sina Vatandoust
- Flinders Medical Centre, Adelaide, Australia. .,Flinders Centre for Innovation in Cancer, Flinders University, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia.
| | - David Wattchow
- Flinders Medical Centre, Adelaide, Australia.,Flinders Centre for Innovation in Cancer, Flinders University, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia
| | - Luigi Sposato
- Flinders Medical Centre, Adelaide, Australia.,Flinders Centre for Innovation in Cancer, Flinders University, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia
| | - Michael Z Michael
- Flinders Medical Centre, Adelaide, Australia.,Flinders Centre for Innovation in Cancer, Flinders University, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia
| | - John Leung
- Flinders Medical Centre, Adelaide, Australia.,GenesisCare, Adelaide, Australia
| | - Kirsten Gormly
- Dr Jones & Partners Medical Imaging, Adelaide, Australia.,University of Adelaide, Adelaide, Australia
| | - Gang Chen
- Monash University, Melbourne, Australia
| | - Erin L Symonds
- Flinders Medical Centre, Adelaide, Australia.,Flinders Centre for Innovation in Cancer, Flinders University, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia
| | - Jeanne Tie
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.,Peter MacCallum Cancer Centre, Melbourne, Australia.,University of Melbourne, Melbourne, Australia
| | - Lito Electra Papanicolas
- Flinders Medical Centre, Adelaide, Australia.,South Australian Health and Medical Research Institute, Adelaide, Australia
| | - Susan Woods
- University of Adelaide, Adelaide, Australia.,South Australian Health and Medical Research Institute, Adelaide, Australia
| | - Val Gebski
- NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
| | - Kelly Mead
- Flinders Medical Centre, Adelaide, Australia
| | | | - Christos S Karapetis
- Flinders Medical Centre, Adelaide, Australia.,Flinders Centre for Innovation in Cancer, Flinders University, Flinders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia
| |
Collapse
|
5
|
Vatandoust S, Bright T, Roy AC, Abbas MN, Watson DI, Gan S, Bull J, Sorich M, Scott-Hoy A, Luu LJ, Karapetis CS. Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study). Asia Pac J Clin Oncol 2021; 18:404-409. [PMID: 34811896 DOI: 10.1111/ajco.13659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 08/04/2021] [Indexed: 12/24/2022]
Abstract
AIMS Gastric cancer with peritoneal involvement has a poor prognosis. Intraperitoneal (IP) paclitaxel has shown promising results in these patients. However, this approach has only been studied in the Asian population, and in combination with S-1. We investigated the maximum tolerated dose of IP paclitaxel, with a standard chemotherapy combination, in the Australian population. METHODS The study of the population included metastatic human epidermal growth factor receptor 2 (HER2) negative gastric adenocarcinoma with peritoneal involvement. Treatment included six 21-day cycles of cisplatin (80 mg/m2 IV, day 1) plus capecitabine (1000 mg/m2 PO BD, days 1-14) plus IP paclitaxel (days 1 and 8). IP paclitaxel doses for cohort 1-3 were 10, 20, and 30 mg/m2 , respectively, in a 3 + 3 standard dose-escalation design. RESULTS Fifteen patients were enrolled of which 6 were female and the median age was 63. Two patients developed dose-limiting toxicities. No grade 4/5 toxicities were recorded. The maximum tolerated dose was not reached. Therefore, as defined by the study protocol, the recommended phase-2 dose for IP paclitaxel was determined to be 30 mg/m2 . The 12-month survival rate was 46.7%, and the median survival was 11.5 months (interquartile range [IQR]: 15.3-6.9). CONCLUSIONS IP paclitaxel is safe in combination with cisplatin and capecitabine and the recommended phase-2 dose is 30 mg/m2 .
Collapse
Affiliation(s)
- Sina Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Tim Bright
- College of Medicine and Public Health, Flinders University, Adelaide, Australia.,Oesophago-Gastric Surgical Unit, Flinders Medical Centre, Bedford Park, Australia
| | - Amitesh Chandra Roy
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Muhammad Nazim Abbas
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - David Ian Watson
- College of Medicine and Public Health, Flinders University, Adelaide, Australia.,Oesophago-Gastric Surgical Unit, Flinders Medical Centre, Bedford Park, Australia
| | - Susan Gan
- College of Medicine and Public Health, Flinders University, Adelaide, Australia.,Oesophago-Gastric Surgical Unit, Flinders Medical Centre, Bedford Park, Australia
| | - Jeff Bull
- Oesophago-Gastric Surgical Unit, Flinders Medical Centre, Bedford Park, Australia
| | - Michael Sorich
- College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Alex Scott-Hoy
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia
| | - Lee-Jen Luu
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia
| | - Christos Stelios Karapetis
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| |
Collapse
|
6
|
Soo A, O'Callaghan ME, Kopsaftis T, Vatandoust S, Moretti K, Kichenadasse G. PSA response to antiandrogen withdrawal: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2021; 24:826-836. [PMID: 33603235 DOI: 10.1038/s41391-021-00337-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 01/08/2021] [Accepted: 01/28/2021] [Indexed: 02/01/2023]
Abstract
BACKGROUND Antiandrogen withdrawal (AAW) response is the paradoxical decrease in prostate-specific antigen (PSA) following the withdrawal of antiandrogen in patients with advanced prostate cancer. Currently, the reported literature on the proportion of patients exhibiting AAW response and the differences in PSA response between the types of antiandrogens is unclear. METHODS This review aimed to explore the PSA response to AAW and to identify if the response depends on the type of antiandrogens. A literature search was performed using databases PubMed, Cochrane and EMBASE with a cut-off date of 23rd of November 2020. Studies reporting on outcomes of AAW and prostate cancer were included. Studies were screened by two reviewers and relevant data extracted. Meta-analysis of outcomes was reported using random-effects and fixed-effects model. A subgroup analysis was performed for type of antiandrogen. RESULTS From 450 studies, 23 were included with a total of 1474 patients with advanced prostate cancer were available for further analysis. Overall, 395 (26%) patients had any reduction in PSA levels (95% CI: 20-32%) and 183 (11%) patients had a ≥50% reduction in PSA levels (95% CI: 6-16%). Among the 1212 patients on first-generation antiandrogens, 30% (95% CI: 23-38%) had any PSA decline with 15% patients having a ≥50% PSA decline (95% CI: 8-22%). In contrast, among the 108 patients on second-generation antiandrogens, 7% (95% CI: 0-13%) had any PSA decline and only 1% (95% CI: 0-5%) had a ≥50% PSA decline. Also, among the 154 patients on androgen synthesis inhibitors, 26% (95% CI: 19-33%) had any PSA decline and only 4% (95% CI: 0-13%) had a ≥50% PSA decline. CONCLUSIONS One-fourth of patients treated with AAW show a PSA response. However, PSA response to AAW is uncommon with second-generation antiandrogens and androgen synthesis inhibitors. Further research is required to understand the differences in response between the types of antiandrogen.
Collapse
Affiliation(s)
- Alwin Soo
- School of Medicine, Flinders University, Bedford Park, SA, Australia
| | - Michael E O'Callaghan
- South Australian Prostate Cancer Clinical Outcomes Collaborative, Flinders Medical Centre, Bedford Park, SA, Australia.,Department of Urology, Flinders Medical Centre, Bedford Park, SA, Australia.,Discipline of Surgery, University of Adelaide, Adelaide, SA, Australia
| | - Tina Kopsaftis
- South Australian Prostate Cancer Clinical Outcomes Collaborative, Flinders Medical Centre, Bedford Park, SA, Australia.,Department of Urology, Flinders Medical Centre, Bedford Park, SA, Australia
| | - Sina Vatandoust
- School of Medicine, Flinders University, Bedford Park, SA, Australia.,Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, Australia
| | - Kim Moretti
- South Australian Prostate Cancer Clinical Outcomes Collaborative, Flinders Medical Centre, Bedford Park, SA, Australia.,Discipline of Surgery, University of Adelaide, Adelaide, SA, Australia.,School of Population Health, University of South Australia, Adelaide, SA, Australia.,Monash University, Clayton, VIC, Australia
| | - Ganessan Kichenadasse
- School of Medicine, Flinders University, Bedford Park, SA, Australia. .,Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, Australia.
| |
Collapse
|
7
|
Burt MG, Mangelsdorf BL, Drake SM, Swan M, Padman S, Vatandoust S, Koczwara B. Insulin sensitivity, cardiovascular function and bone health in women with early stage breast cancer before and after cancer treatment. Intern Med J 2021; 52:1917-1924. [PMID: 34343400 DOI: 10.1111/imj.15469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 07/06/2021] [Accepted: 07/11/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND Cardiovascular disease is a leading cause of death in breast cancer survivors, but the underlying cause is not fully characterised. AIMS To determine whether insulin sensitivity, cardiovascular risk markers and body composition were perturbed in women treated with chemotherapy for early stage breast cancer and whether perturbations occurred before or after cancer treatment. METHODS Sixteen women with breast cancer and 17 control subjects were studied. Twelve breast cancer patients returned for a second visit following cancer treatment comprising chemotherapy (n=2), or chemotherapy and radiotherapy (n=10)). Matsuda index to estimate insulin sensitivity, fasting lipids, pulse wave velocity (PWV), reactive hyperaemia index (RHI), and body composition by dual energy X-ray absorptiometry were measured. RESULTS There were no significant differences in age (53±9 vs 54±11 years, p=0.82) or body mass index (28±7 vs 28±6, p=0.97) between patients with breast cancer and controls. Patients with breast cancer had higher triglycerides than controls (1.2±0.1 vs 0.8±0.1 mmol/L, p=0.03), but there were no significant differences in Matsuda index, PWV and RHI. Following cancer treatment there was a lower Matsuda index (6.3±1.2 vs 5.2±1.0, p=0.01), but this was not associated with a significant change in vascular function. Bone mass fell by 3% from 2.27±0.11 to 2.20±0.10 kg after cancer treatment (p=0.03). CONCLUSIONS Patients with breast cancer had higher triglycerides before treatment and a reduction in insulin sensitivity and bone mass following cancer treatment. Future larger and longer-term studies should characterise the effect of reduced insulin sensitivity on rates of diabetes, cardiovascular disease, cancer outcomes and fracture. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Morton G Burt
- Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Brenda L Mangelsdorf
- Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, Australia
| | - Sophie M Drake
- Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, Australia
| | - Monique Swan
- Southern Adelaide Health Service, Flinders Medical Centre, Adelaide, Australia
| | - Sunita Padman
- Southern Adelaide Health Service, Flinders Medical Centre, Adelaide, Australia
| | - Sina Vatandoust
- College of Medicine and Public Health, Flinders University, Adelaide, Australia.,Southern Adelaide Health Service, Flinders Medical Centre, Adelaide, Australia
| | - Bogda Koczwara
- College of Medicine and Public Health, Flinders University, Adelaide, Australia.,Southern Adelaide Health Service, Flinders Medical Centre, Adelaide, Australia
| |
Collapse
|
8
|
Abbas MN, Klevansky M, Koczwara B, Roy AC, Sukumaran S, Vatandoust S, Karapetis CS. Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer. Cancer Rep (Hoboken) 2021; 5:e1487. [PMID: 34196124 PMCID: PMC8955060 DOI: 10.1002/cnr2.1487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 05/14/2021] [Accepted: 06/14/2021] [Indexed: 11/17/2022] Open
Abstract
Background Nivolumab improves disease control and survival in advanced NSCLC in patients with good performance status (PS), but there is limited data on its efficacy in patients with poor PS. Aim Primary objective of the study was to evaluate the efficacy and safety of nivolumab and examine the influence of PS on outcomes. Methods and Results Retrospective analysis of patients treated with single‐agent nivolumab for advanced NSCLC at a single institution was performed. Sixty‐six patients treated with nivolumab were identified (33 male) with a median age of 68.5 years. Fifty‐six (85%) patients were current or former smokers and 17 (26%) had brain metastasis. All patients had received prior chemotherapy, 39 (59%) patients received one and 27 (41%) had ≥2 prior lines of therapy. Median overall survival (OS) was 7.1 months (95%CI 3.61–11.3) in the overall study population. OS of patients with PS ≥2 at the start of treatment was 3.04 months (95%CI 1.64–7.36) as compared to 10.23 months (95%CI 7.06–18.9) with PS ≤1. The overall response rate was 7% (four patients had a partial response), 23 (40%) patients had stable disease; the overall disease control rate (partial response and stable disease) was 47%. Twenty‐six (40%) patients had PS ≥2 at the start of treatment and 2 (8%) of these patients developed a partial response, 4 (15%) had stable disease; the overall disease control rate was 23%. Fourteen (58%) patients with PS ≥2 had disease progression at the time of first disease response evaluation. In the overall population, 20% of patients experienced grade ≥3 treatment‐related adverse events (TRAEs), most commonly pneumonitis, hepatitis, and colitis. Fourteen TRAEs led to treatment discontinuation, 9 (23%) adverse events (AEs) in patients with PS ≤1 and 5 (19%) with PS ≥2. Fourteen (21%) patients died within 30 days of the last nivolumab treatment. Conclusion There was no significant difference in toxicity leading to treatment discontinuation between the poor and good PS groups, but survival was shorter with poorer PS. PS appears to be an important prognostic factor and remains a relevant discriminator in the selection of treatment with immunotherapy for lung cancer.
Collapse
Affiliation(s)
- M Nazim Abbas
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Myron Klevansky
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia
| | - Bogda Koczwara
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Amitesh Chandra Roy
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Shawgi Sukumaran
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Sina Vatandoust
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| | - Christos Stelios Karapetis
- Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, South Australia, Australia.,College of Medicine and Public Health, Flinders University, Adelaide, Australia
| |
Collapse
|
9
|
Mikaeel RR, Symonds EL, Kimber J, Smith E, Horsnell M, Uylaki W, Tapia Rico G, Hewett PJ, Yong J, Tonkin D, Jesudason D, Poplawski NK, Ruszkiewicz AR, Drew PA, Hardingham JE, Wong S, Frank O, Tomita Y, Patel D, Vatandoust S, Townsend AR, Roder D, Young GP, Parry S, Tomlinson IP, Wittert G, Wattchow D, Worthley DL, Brooks WJ, Price TJ, Young JP. Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pac J Clin Oncol 2020; 17:131-138. [PMID: 32885561 DOI: 10.1111/ajco.13428] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 06/20/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND Colorectal cancer (CRC) is rising in incidence in young adults, and this observation is currently unexplained. We investigated whether having a personal history of type 2 diabetes mellitus (T2D) was a potential risk factor for young-onset colorectal cancer (YOCRC). METHODS The South Australian Young Onset (SAYO) CRC study is a series of young adults with CRC below age 55. Ninety unrelated YOCRC cases were recruited to the study. Personal history and detailed family history of T2D were obtained at face-to-face interview and confirmed from medical records. Whole exome sequencing was conducted on germline DNA from each CRC case. Controls for personal history studies of T2D were 240 patients with proven clear colonoscopies and no known CRC predispositions. RESULTS The median age of YOCRC cases was 44 years (18-54) and of controls was 45 years (18-54), and 53% of both cases and controls were females (P = 0.99). Left-sided (distal) CRC was seen in 67/89 (75%) of cases. A personal history of T2D was confirmed in 17/90 (19%) YOCRC patients compared with controls (12/240, 5%; P < 0.001; odds ratio = 4.4; 95% confidence interval, 2.0-9.7). YOCRC patients frequently reported at least one first-degree relative with T2D (32/85, 38%). Ten of 87 (12%) of YOCRC cases had CRC-related pathogenic germline variants, however, no pathogenic variants in familial diabetes-associated genes were seen. CONCLUSIONS Though the mechanism remains unclear, our observations suggest that there is enrichment for personal history of T2D in YOCRC patients. IMPACT A diagnosis of T2D could therefore potentially identify a subset of young adults at increased risk for CRC and in whom early screening might be appropriate.
Collapse
Affiliation(s)
- Reger R Mikaeel
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.,SAHMRI Colorectal Node, Basil Hetzel Institute, Woodville South, South Australia, Australia.,Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.,Biology Department, College of Science, University of Duhok, Duhok, Kurdistan, Iraq
| | - Erin L Symonds
- Bowel Health Service, Flinders Medical Centre, Bedford Park, South Australia, Australia.,Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, South Australia, Australia
| | - James Kimber
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| | - Eric Smith
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.,University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Mehgan Horsnell
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Wendy Uylaki
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.,Department of Gastroenterology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Gonzalo Tapia Rico
- Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
| | - Peter J Hewett
- University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Jonathan Yong
- University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Darren Tonkin
- University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - David Jesudason
- Department of Endocrinology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Nicola K Poplawski
- Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.,Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| | - Andrew R Ruszkiewicz
- Division of Anatomical Pathology, SA Pathology, Adelaide, South Australia, Australia.,Centre for Cancer Biology, University of South Australia, Adelaide, South Australia, Australia
| | - Paul A Drew
- University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Jenny E Hardingham
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.,SAHMRI Colorectal Node, Basil Hetzel Institute, Woodville South, South Australia, Australia.,Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| | - Stephanie Wong
- Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia
| | - Oliver Frank
- Discipline of General Practice, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| | - Yoko Tomita
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - Dainik Patel
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.,Department of Medical Oncology, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia
| | - Sina Vatandoust
- Flinders Medical Centre, Bedford Park, South Australia, Australia
| | - Amanda R Townsend
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
| | - David Roder
- Cancer Epidemiology and Population Health, University of South Australia, Adelaide, South Australia, Australia
| | - Graeme P Young
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, South Australia, Australia
| | - Susan Parry
- New Zealand Familial GI Cancer Service, Auckland City Hospital, Auckland, New Zealand.,National Bowel Screening Programme, Ministry of Health, New Zealand
| | - Ian P Tomlinson
- Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
| | - Gary Wittert
- Discipline of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| | - David Wattchow
- Flinders University, Flinders Medical Centre, Bedford Park, South Australia, Australia
| | - Daniel L Worthley
- South Australian Health & Medical Research Institute & School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
| | - William J Brooks
- Adelaide Medical Solutions, Adelaide Health Solutions, Woodville, South Australia, Australia
| | - Timothy J Price
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.,Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| | - Joanne P Young
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.,SAHMRI Colorectal Node, Basil Hetzel Institute, Woodville South, South Australia, Australia.,Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia
| |
Collapse
|
10
|
Ayoola A, Sukumaran S, Jain K, Kumar R, Gordon D, Honda-Okubo Y, Quinn S, Roy A, Vatandoust S, Koczwara B, Kichenadasse G, Richards A, Mead K, Karapetis C. Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study. Support Care Cancer 2020; 28:5411-5417. [PMID: 32144585 DOI: 10.1007/s00520-020-05384-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 02/26/2020] [Indexed: 11/27/2022]
Abstract
PURPOSE Influenza virus infection has significant morbidity and mortality in patients with medical co-morbidities who are also immunosuppressed. The efficacy of the seasonal influenza vaccine has not been well studied in patients receiving chemotherapy. We assessed the efficacy of seasonal influenza vaccine in patients with non-haematological malignancy on active treatment (chemotherapy and targeted therapy). METHODS A prospective single arm, open label study with 53 patients with non-haematological cancers recruited during the 2011 and 2012 influenza seasons. Participants had one dose of 2011/2012 trivalent vaccine containing strains A/California/7/2009(H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 (Fluvax) prior to or in-between treatment cycles. Haemagglutination inhibition antibody (HIA) titres in serum were measured at baseline 3, 6 and 24 weeks. Primary endpoint: seroconversion rate (SCR) at 3 weeks. Secondary endpoints: late SCR at 6 weeks. rate of sustained sero-protection titres (SPR) at 24 weeks. Seroconversion was defined as postvaccination ≥ 4-fold increase in HIA titre and sero-protection defined as a HIA ≥ 1:40. RESULTS The SCR at 3 weeks were 35%, 30% and 22.5% to the H1N1, H3N2 and B/Bris strains, respectively. There were no new cases of late SC at 6 weeks or 24 weeks. The SPR at 3 weeks were 72.5%, 65% and 40%, respectively, to H1N1, H3N2 and B/Bris. The SPR at 24 weeks to H1N1, H3N2 and B/Bris were 40%, 52.5% and 17.5%, respectively. CONCLUSIONS Patients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24 weeks postvaccination.
Collapse
Affiliation(s)
- A Ayoola
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia.
| | - S Sukumaran
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - K Jain
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - R Kumar
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - D Gordon
- Department of Microbiology and Infectious Diseases, Flinders University and Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - Y Honda-Okubo
- Department of Endocrinology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - S Quinn
- Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Melbourne, 3122, Australia
| | - A Roy
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - S Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - B Koczwara
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - G Kichenadasse
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - A Richards
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - K Mead
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - C Karapetis
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| |
Collapse
|
11
|
Reece M, Saluja H, Hollington P, Karapetis CS, Vatandoust S, Young GP, Symonds EL. The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. Front Genet 2019; 10:1118. [PMID: 31824558 PMCID: PMC6881479 DOI: 10.3389/fgene.2019.01118] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Accepted: 10/16/2019] [Indexed: 12/20/2022] Open
Abstract
Background: Colorectal cancer is one of the most common cancers worldwide and has a high mortality rate following disease recurrence. Treatment efficacy is maximized by providing tailored cancer treatment, ideally involving surgical resection and personalized neoadjuvant and adjuvant therapies, including chemotherapy, radiotherapy and increasingly, targeted therapy. Early detection of recurrence or disease progression results in more treatable disease and is essential to improving survival outcomes. Recent advances in the understanding of tumor genetics have resulted in the discovery of circulating tumor DNA (ctDNA). A growing body of evidence supports the use of these sensitive biomarkers in detecting residual disease and diagnosing recurrence as well as enabling targeted and tumor-specific adjuvant therapies. Methods: A literature search in Pubmed was performed to identify all original articles preceding April 2019 that utilize ctDNA for the purpose of monitoring response to colorectal cancer treatment. Results: Ninety-two clinical studies were included. These studies demonstrate that ctDNA is a reliable measure of tumor burden. Studies show the utility of ctDNA in assessing the adequacy of surgical tumor clearance and changes in ctDNA levels reflect response to systemic treatments. ctDNA can be used in the selection of targeted treatments. The reappearance or increase in ctDNA, as well as the emergence of new mutations, correlates with disease recurrence, progression, and resistance to therapy, with ctDNA measurement allowing more sensitive monitoring than currently used clinical tools. Conclusions: ctDNA shows enormous promise as a sensitive biomarker for monitoring response to many treatment modalities and for targeting therapy. Thus, it is emerging as a new way for guiding treatment decisions-initiating, altering, and ceasing treatments, or prompting investigation into the potential for residual disease. However, many potentially useful ctDNA markers are available and more work is needed to determine which are best suited for specific purposes and for improving specific outcomes.
Collapse
Affiliation(s)
- Mifanwy Reece
- Colorectal Surgery, Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, SA, Australia
| | - Hariti Saluja
- Department of Medicine, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.,Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia
| | - Paul Hollington
- Colorectal Surgery, Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, SA, Australia
| | - Christos S Karapetis
- Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.,Department of Medical Oncology, Flinders Medical Centre, Bedford Park, SA, Australia
| | - Sina Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, SA, Australia
| | - Graeme P Young
- Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia
| | - Erin L Symonds
- Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.,Bowel Health Service, Flinders Medical Centre, Bedford Park, SA, Australia
| |
Collapse
|
12
|
Vatandoust S, Bright T, Roy AC, Watson D, Gan S, Bull J, Abbas MN, Karapetis CS. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol. BMJ Open 2019; 9:e026732. [PMID: 31061042 PMCID: PMC6501970 DOI: 10.1136/bmjopen-2018-026732] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
INTRODUCTION Gastric cancer with peritoneal metastasis has a poor outcome. Only a few studies have specifically investigated this group of patients. Japanese researchers have shown that chemotherapy with intraperitoneal paclitaxel (IPP) and oral S-1 (tegafur/gimeracil/oteracil) is active and well tolerated. These results have been achieved in a specific genetic pool (Japanese population), using regimens that may not be available in other parts of the world. We have designed this phase I trial to investigate IPP in combination with a standard chemotherapy combination in these patients. METHODS We use a 3+3 expanded cohort dose escalation until a predefined number of dose-limiting toxicities are reached. Patients will have an intraperitoneal catheter placed surgically after trial enrolment. Chemotherapy includes a maximum of six cycles (21 days) of capecitabine (X) (1000 mg/m2 two times a day, days 1-14)+cisplatin (C) (intravenous 80 mg/m2 day 1) and IPP (days 1 and 8) with the following doses: cohort-1: 10 mg/m2, cohort-2: 20 mg/m2 and cohort-3: 30 mg/m2. Primary endpoint is to determine the maximum tolerated dose of IPP. Secondary endpoints include determining the safety and tolerability of IPP in combination with C and X, overall response rates, ascites response rate, progression-free survival, overall survival and effects on quality of life.Important inclusion criteria include age ≥18 years, human epidermal growth factor receptor 2 non-amplified gastric adenocarcinoma with histological or cytology-proven peritoneal involvement and adequate organ function. Exclusion criteria include previous malignancy within 5 years, recent abdominal or pelvic radiation treatment, significant abdominal adhesions or sepsis. ETHICS AND DISSEMINATION The study is approved by Southern Adelaide Clinical Human Research Ethics Committee. A manuscript will be prepared for publication on the completion of the trial. This study will be conducted according to the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) annotated with TGA comments (Therapeutic Goods Administration DSEB July 2000) and in compliance with applicable laws and regulations. The study will be performed in accordance with the NHMRC Statement on Ethical Conduct in Research Involving Humans (© Commonwealth of Australia 2007), and the NHMRC Australian Code for the Responsible Conduct of Research (©Australian Government 2007), and the principles laid down by the World Medical Assembly in the Declaration of Helsinki 2008. TRIAL REGISTRATION NUMBER ACTRN12614001063606.
Collapse
Affiliation(s)
- Sina Vatandoust
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
- School of Medicine, Flinders University, Adelaide, South Australia, Australia
| | - Tim Bright
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
- School of Medicine, Flinders University, Adelaide, South Australia, Australia
| | - Amitesh Chandra Roy
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
- School of Medicine, Flinders University, Adelaide, South Australia, Australia
| | - David Watson
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
- School of Medicine, Flinders University, Adelaide, South Australia, Australia
| | - Susan Gan
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
- School of Medicine, Flinders University, Adelaide, South Australia, Australia
| | - Jeff Bull
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
| | - Muhammad Nazim Abbas
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
| | - Christos Stelios Karapetis
- Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia
- School of Medicine, Flinders University, Adelaide, South Australia, Australia
| |
Collapse
|
13
|
Chang Lee R, Sukumaran S, Koczwara B, Woodman R, Kichenadasse G, Roy A, Vatandoust S, Karapetis C. Patterns of care in Jehovah's Witnesses patients with solid tumours and lymphoma. Cancer Rep (Hoboken) 2019; 2:e1148. [PMID: 32721085 DOI: 10.1002/cnr2.1148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 10/08/2018] [Accepted: 10/08/2018] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND Supportive care of Jehovah's Witnesses (JWs) diagnosed with cancer can be challenging, as they do not accept red blood cell (RBC) transfusions. AIM The study was designed to determine treatment preferences and pattern of care offered to JWs diagnosed with cancer and its impact on cancer management. METHODS AND RESULTS A retrospective cohort study of JWs with solid malignancies or lymphoma in our institution between 2005 and 2015 was conducted. Survival statistics were estimated using Kaplan Meier survival curves and Cox proportional regression model. A total of 63 JWs were identified with a median age of 70 years. At diagnosis, 34% (n = 22) had anaemia. All 63 declined RBC transfusion, including 19 patients who later developed transfusion threshold during anti-cancer treatment. Forty-three percent (n = 27) JWs had advanced (stage 4) disease, and 76% (n = 48) had Eastern Cooperative Oncology Group of 0 to 1. JWs were willing to accept surgery and radiation rather than chemotherapy. Treatment was deemed to be suboptimal in 22% (n = 14) JWs due to early treatment discontinuation, administration of non-standard chemotherapy regimen, or dose reduction due to anaemia and denial of blood transfusion. Twenty-seven percent (n = 17) received hematopoietic growth factors (erythropoiesis-stimulating agents and pegfilgrastim). There was no mortality directly attributed to anaemia or refusal of blood transfusion in the entire cohort. CONCLUSION Jehovah's Witnesses declined RBC transfusion at diagnosis and during cancer therapy even if medically indicated. Management pathways need to be prospectively defined for this group of patients.
Collapse
Affiliation(s)
| | - Shawgi Sukumaran
- Flinders Medical Centre, FCIC, Bedford Park, SA, 5042, Australia.,Flinders University, Bedford Park, SA, 5042, Australia
| | - Bogda Koczwara
- Flinders Medical Centre, FCIC, Bedford Park, SA, 5042, Australia.,Flinders University, Bedford Park, SA, 5042, Australia
| | | | - Ganessan Kichenadasse
- Flinders Medical Centre, FCIC, Bedford Park, SA, 5042, Australia.,Flinders University, Bedford Park, SA, 5042, Australia
| | - Amitesh Roy
- Flinders Medical Centre, FCIC, Bedford Park, SA, 5042, Australia.,Flinders University, Bedford Park, SA, 5042, Australia
| | - Sina Vatandoust
- Flinders Medical Centre, FCIC, Bedford Park, SA, 5042, Australia.,Flinders University, Bedford Park, SA, 5042, Australia
| | - Chris Karapetis
- Flinders Medical Centre, FCIC, Bedford Park, SA, 5042, Australia.,Flinders University, Bedford Park, SA, 5042, Australia
| |
Collapse
|
14
|
Kemp E, Koczwara B, Turner J, Girgis A, Schofield P, Hulbert-Williams N, Levesque J, Spence D, Vatandoust S, Kichenadasse G, Roy A, Sukumaran S, Karapetis CS, Richards C, Fitzgerald M, Beatty L. Internet use and preferences among women living with advanced breast cancer. Breast J 2019; 25:290-295. [PMID: 30790383 DOI: 10.1111/tbj.13203] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 12/21/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Emma Kemp
- College of Medicine and Public Health; Flinders University; Adelaide Australia
| | - Bogda Koczwara
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Jane Turner
- School of Medicine; University of Queensland; Herston Australia
| | - Afaf Girgis
- South Western Sydney Clinical School; University of New South Wales; Sydney Australia
- Ingham Institute for Applied Medical Research; Liverpool Australia
| | | | | | - Janelle Levesque
- South Western Sydney Clinical School; University of New South Wales; Sydney Australia
| | | | - Sina Vatandoust
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Ganessan Kichenadasse
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Amitesh Roy
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Shawgi Sukumaran
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Christos S. Karapetis
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Caroline Richards
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Michael Fitzgerald
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| | - Lisa Beatty
- College of Medicine and Public Health; Flinders University; Adelaide Australia
- Flinders Centre for Innovation in Cancer; Flinders Medical Centre; Bedford Park Australia
| |
Collapse
|
15
|
Sposato LA, Lam Y, Karapetis C, Vatandoust S, Roy A, Hakendorf P, Dwyer A, de Fontgalland D, Hollington P, Wattchow D. Observation of "complete clinical response" in rectal cancer after neoadjuvant chemoradiation: The Flinders experience. Asia Pac J Clin Oncol 2018; 14:439-445. [PMID: 29932278 DOI: 10.1111/ajco.12993] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2017] [Accepted: 04/29/2018] [Indexed: 01/17/2023]
Abstract
AIM Observation with close follow-up ("watch and wait") is a recognized treatment option in patients who achieve a complete clinical response to long course chemoradiotherapy. This review of a prospective database aims to evaluate the clinical outcomes among patients with a complete clinical response managed with observation. METHODS A prospective study of 32 patients who achieved a complete clinical response was undertaken. The primary outcomes measured were overall and recurrence-free survival, and rate of organ preservation in patients who deferred immediate surgery. RESULTS Seven patients developed local regrowth over a median follow-up period of 38 months (range, 9-91 months). Median time to detection was 12 months. All seven underwent salvage surgery with complete surgical clearance. One patient developed combined local and systemic recurrence following a low anterior resection. Organ preservation was possible in 25 (78%) patients who sustained a complete clinical response with no evidence of local regrowth or disease recurrence. Among the patients who sustained a complete response, two developed isolated systemic disease. Overall and recurrence-free survival was 95.7% and 87.0%, respectively. CONCLUSION The majority of patients with rectal cancer who achieved a complete clinical response after chemoradiotherapy and managed with a "watch and wait" approach preserved their rectum and did not develop cancer relapse. Salvage surgery was achieved in all patients who developed local regrowth. The study supports a period of observation in rectal cancer patients who achieve a complete clinical response.
Collapse
Affiliation(s)
- Luigi A Sposato
- Department of Surgery, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Yick Lam
- Department of Surgery, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Chris Karapetis
- Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Sina Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Amitesh Roy
- Department of Medical Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Paul Hakendorf
- Department of Epidemiology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Andrew Dwyer
- Department of Radiology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Dayan de Fontgalland
- Department of Surgery, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - Paul Hollington
- Department of Surgery, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| | - David Wattchow
- Department of Surgery, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia
| |
Collapse
|
16
|
Vatandoust S, Kichenadasse G, O'Callaghan M, Vincent AD, Kopsaftis T, Walsh S, Borg M, Karapetis CS, Moretti K. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry. BJU Int 2018; 121 Suppl 3:48-54. [PMID: 29603585 DOI: 10.1111/bju.14228] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Sina Vatandoust
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide SA Australia
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- Department of Medical Oncology; Flinders Medical Centre; Bedford Park SA Australia
| | - Ganessan Kichenadasse
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide SA Australia
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- Department of Medical Oncology; Flinders Medical Centre; Bedford Park SA Australia
| | - Michael O'Callaghan
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide SA Australia
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- Urology Unit; Repatriation General Hospital, Daw Park; Adelaide SA Australia
- Freemasons Foundation Centre for Men's Health; Adelaide SA Australia
- University of Adelaide; Adelaide SA Australia
| | - Andrew D. Vincent
- Freemasons Foundation Centre for Men's Health; Adelaide SA Australia
- University of Adelaide; Adelaide SA Australia
| | - Tina Kopsaftis
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- Urology Unit; Repatriation General Hospital, Daw Park; Adelaide SA Australia
| | - Scott Walsh
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- Urology Unit; Repatriation General Hospital, Daw Park; Adelaide SA Australia
| | - Martin Borg
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- University of Adelaide; Adelaide SA Australia
- Adelaide Radiotherapy Centre; Adelaide SA Australia
| | - Christos S. Karapetis
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide SA Australia
- Department of Medical Oncology; Flinders Medical Centre; Bedford Park SA Australia
| | - Kim Moretti
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide SA Australia
- The South Australian Prostate Cancer Clinical Outcomes Collaborative; Adelaide SA Australia
- Freemasons Foundation Centre for Men's Health; Adelaide SA Australia
- University of Adelaide; Adelaide SA Australia
- University of South Australia; Adelaide SA Australia
| |
Collapse
|
17
|
Vatandoust S, Bright TI, Roy AC, Klevansky M, Bull J, Karapetis CS. Phase I open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.tps201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS201 Background: There have been few studies investigating advanced gastric cancer with peritoneal involvement and ascites, showing poor survival in these patients. Researchers from Japan have shown that chemotherapy with IPP and Oral S-1 (tegafur/gimeracil/oteracil) is active in these patients. These results have been achieved in a different genetic pool (Japanese population) compared with Australia, using regimens that are not available here. We have designed this phase I trial to investigate the Maximum Tolerated Dose (MDT) of IPP in combination with a standard chemotherapy combination (C+X) in these patients. Methods: This is an open-label, single centre, phase I trial with 3+3 expanded cohort design. Patients will have an IP catheter placed surgically after trial enrolment. Study was approved by the relevant ethics committee. Chemotherapy: maximum of six 21-day cycles of: X (PO, 1000 mg/m2 BD days 1-14) + C (IV 80mg/m2 day 1) + IPP (day 1 and 8) with the following doses: Cohort-1: 10 mg/m2, Cohort-2: 20 mg/m2 and Cohort-3: 30 mg/m2. Important inclusion criteria: age ≥ 18 years, signed written informed consent, HER-2 non-amplified gastric adenocarcinoma with biopsy or cytology showing peritoneal involvement and/or ascites, adequate organ function and signed consent. Important exclusion criteria: history of another malignancy within 5 years, life expectancy < 3months, peripheral neuropathy, recent ( < 4 weeks) abdominal or pelvic radiation treatment, significant intra-abdominal adhesions or active intra-abdominal sepsis. Cohorts 1 and 2 have been completed. Enrolment to cohort-3 is beginning in October 2017. Clinical trial information: ACTRN12614001063606.
Collapse
Affiliation(s)
| | - Tim I. Bright
- Flinders University Medical Centre, Adelaide, Australia
| | | | | | - Jeff Bull
- Flinders University Medical Centre, Adelaide, Australia
| | | |
Collapse
|
18
|
Klevansky M, Vatandoust S, Dykes L, Padbury R, Price TJ, Roder D, Moore J, Piantadosi C, Roy A, Karapetis C. The impact of primary tumour resection and sidedness in patients with synchronous metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
739 Background: The benefit of primary tumour resection (PTR) in patients with synchronous mCRC is not clear. The influence of tumour location on PTR benefit is also uncertain. Methods: SAMCRC is a population based registry collating data from all patients in South Australia diagnosed with mCRC from February 2006. We examined outcomes according to whether the primary colorectal tumour was excised within 3 months of diagnosis or remained in situ; we also examined whether outcomes were affected by tumour side (right v left). Registry data was included for patients with synchronous metastic adenocarcinoma from colon or rectum. Exclusion criteria included metastasectomy, tumour resection within 7 days or death within 3 months of mCRC diagnosis. Kaplan Meier analysis was used for Survival. Tumour sidedness and PTR were analysed with a multivariate Cox proportional hazards model. Survival was measured from the landmark date (3 months from date of diagnosis). Results: 2575 patients with synchronous mCRC have entered the database, of which 1869 patients were eligible for the PTR analysis. 50.2% (n = 938) underwent PTR. 481 patients (51.3%) of the PTR analysis group had left-sided primary tumours whilst 436 had right sided tumours (46.5%) which was significant (p < 0.001). 63% of the PTR cohort were male (n = 1006). Site and age metastases were included in the multivariate analysis. PTR was associated with improved survival from landmark compared to no resection (15.0 mo vs 11.2 mo, 95% CI 15.0 – 16.3 vs 11.2 – 12.3, p = 0.031). In the entire synchronous mCRC group, left-sided tumours (62.1%) had a longer median survival (17.8 mo vs 10.4 mo, 95% CI 15.7 – 19.5 vs 10.4 – 11.7 p = < 0.001). An interaction test was performed for sidedness and was not significant. Conclusions: PTR was associated was associated with improvement in survival in this large population based registry. This finding did not differ signifcantly between right and left sided tumours. Survival was superior for patients with left sided tumours, in keeping with established data. Criteria for selection of patients with mCRC who benefit from PTR need to be defined.
Collapse
Affiliation(s)
| | | | | | - Rob Padbury
- Flinders University Medical Centre, Adelaide, Australia
| | - Timothy Jay Price
- Queen Elizabeth Hospital/ University of Adelaide, Adelaide, Australia
| | - David Roder
- University of South Australia, Adelaide, Australia
| | | | | | - Amitesh Roy
- Flinders University Medical Centre, Adelaide, Australia
| | | |
Collapse
|
19
|
Chang R, Sukumaran S, Woodman RJ, Kichenadasse G, Karapetis CS, Koczwara B, Vatandoust S, Roy AC. Outcomes of solid tumor malignancies in patients of Jehovah’s Witness faith. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e18176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18176 Background: Jehovah's Witness (JW) patients with cancer present unique challenges due to their refusal of blood and blood products which limits supportive care options in the setting of cancer treatment. This study was aimed at determining their cancer specific outcomes. Methods: A retrospective analysis of case records of JW with solid tumors presented between 2005 and 2015 was conducted. Patient demographic data, diagnosis, treatment details and survival outcomes were collected and analysed. Results: A total of 63 JW were identified (39 females; 24 males); median age was 70 years (25-90). The most common cancer was breast (n=16) followed by colorectal (n=10). 27 JW had advanced disease (TNM stage 4), 48 patients had ECOG 0-1 and 22 JW had anaemia (Hb<120g/L for women and <130g/L for men) at the time of diagnosis. While surgery and radiation were uniformly accepted when recommended, 7 out of 42 refused chemotherapy. Median OS was 64 months in early stage (TNM stages 1-3) and 11 months in advanced stage. At presentation blood transfusion was considered unacceptable by all patients under any circumstances. 19 patients rejected transfusion even after symptomatic or life threatening anaemia. They had 1 year overall survival rate of 42% compared with 84% for those who did not require transfusion (HR 4.31, CI 1.96- 9.49, P=0.001). When adjusted for age and ECOG, these results were significant in early stage (P <0.026) but not in late stage (P= 0.6). Treatment was suboptimal in 14 JW patients due to early treatment discontinuation or inferior chemotherapy regimen used to avoid pancytopenia. Median OS in this group was 15 months compared to 46 months who had optimal treatment (HR 2.5, CI 1.07- 6.27, P =0.034). 17 JW received bone marrow stimulating agents like erythropoietin or G-CSF. They helped with dyspnoea and maintaining chemotherapy dose intensity. Conclusions: Refusal of blood components may have negative impact on long term cancer outcome of JW due to compromised chemotherapy dose intensity. Strategies to deliver optimum therapy while being sensitive of religious perceptions will help in improving outcomes for this group.
Collapse
Affiliation(s)
| | | | | | - Ganessan Kichenadasse
- Flinders Medical Centre and Flinders Centre for Innovation in Cancer, Bedford Park, Australia
| | | | - Bogda Koczwara
- Flinders Centre for Innovation in Cancer, Bedford Park, Australia
| | - Sina Vatandoust
- Flinders Medical Centre and Flinders Centre for Innovation in Cancer, Adelaide, Australia
| | | |
Collapse
|
20
|
Wong S, Lidums I, Rosty C, Ruszkiewicz A, Parry S, Win AK, Tomita Y, Vatandoust S, Townsend A, Patel D, Hardingham JE, Roder D, Smith E, Drew P, Marker J, Uylaki W, Hewett P, Worthley DL, Symonds E, Young GP, Price TJ, Young JP. Findings in young adults at colonoscopy from a hospital service database audit. BMC Gastroenterol 2017; 17:56. [PMID: 28424049 PMCID: PMC5395776 DOI: 10.1186/s12876-017-0612-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 04/10/2017] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Colorectal cancer (CRC) diagnosed at <50 years is predominantly located in the distal colon and rectum. Little is known about which lesion subtypes may serve as CRC precursors in young adults. The aim of this work was to document the prevalence and histological subtype of lesions seen in patients aged <50 years, and any associated clinical features. METHODS An audit of the colonoscopy database at The Queen Elizabeth Hospital in Adelaide, South Australia over a 12-month period was undertaken. Findings were recorded from both colonoscopy reports and corresponding histological examination of excised lesions. RESULTS Data were extracted from colonoscopies in 2064 patients. Those aged <50 comprised 485 (24%) of the total. CRC precursor lesions (including sessile serrated adenoma/polyps (SSA/P), traditional serrated adenomas, tubular adenomas ≥10 mm or with high-grade dysplasia, and conventional adenomas with villous histology) were seen in 4.3% of patients aged <50 and 12.9% of patients aged ≥50 (P <0.001). Among colonoscopies yielding CRC precursor lesions in patients under 50 years, SSA/P occurred in 52% of procedures (11/21), compared with 27% (55/204) of procedures in patients aged 50 and older (P = 0.02). SSA/P were proximally located in (10/11) 90% of patients aged under 50, and 80% (43/54) of those aged 50 and older (P = 0.46). CONCLUSIONS SSA/P were the most frequently observed CRC precursor lesions in patients aged <50. Most CRCs in this age group are known to arise in the distal colon and rectum suggesting that lesions other than SSA/P may serve as the precursor for the majority of early-onset CRC.
Collapse
Affiliation(s)
- Stephanie Wong
- Department of Gastroenterology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Ilmars Lidums
- Department of Gastroenterology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Christophe Rosty
- Envoi Specialist Pathologists, Kelvin Grove 4059, Brisbane, QLD, Australia.,School of Medicine, University of Queensland, Herston 4006, Brisbane, QLD, Australia.,Department of Pathology, Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, The University of Melbourne, Parkville 3010, Melbourne, VIC, Australia
| | - Andrew Ruszkiewicz
- Division of Anatomical Pathology, SA Pathology, Adelaide, 5000, South Australia, Australia.,Centre for Cancer Biology, University of South Australia, Adelaide, 5000, South Australia, Australia
| | - Susan Parry
- Familial GI Cancer Service and Ministry of Health Bowel Cancer Programme, Auckland City Hospital, Auckland, New Zealand
| | - Aung Ko Win
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville 3010, Melbourne, VIC, Australia
| | - Yoko Tomita
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Sina Vatandoust
- Flinders Medical Centre, Bedford Park 5042, Adelaide, South Australia, Australia
| | - Amanda Townsend
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Dainik Patel
- Flinders Medical Centre, Bedford Park 5042, Adelaide, South Australia, Australia
| | - Jennifer E Hardingham
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia.,School of Medicine, University of Adelaide, Adelaide, 5000, South Australia, Australia
| | - David Roder
- Cancer Epidemiology and Population Health, University of South Australia, Adelaide, 5000, South Australia, Australia
| | - Eric Smith
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia.,School of Medicine, University of Adelaide, Adelaide, 5000, South Australia, Australia
| | - Paul Drew
- School of Nursing and Midwifery, Flinders University, Bedford Park 5042, Adelaide, South Australia, Australia.,Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Julie Marker
- Cancer Voices SA, Kensington Park 5068, Adelaide, South Australia, Australia
| | - Wendy Uylaki
- Department of Gastroenterology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia.,Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Peter Hewett
- University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia
| | - Daniel L Worthley
- School of Medicine, University of Adelaide, Adelaide, 5000, South Australia, Australia.,Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, 5000, South Australia, Australia
| | - Erin Symonds
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park 5042, Adelaide, South Australia, Australia.,Bowel Health Service, Repatriation General Hospital, Daw Park 5041, Adelaide, South Australia, Australia
| | - Graeme P Young
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park 5042, Adelaide, South Australia, Australia
| | - Timothy J Price
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia.,School of Medicine, University of Adelaide, Adelaide, 5000, South Australia, Australia
| | - Joanne P Young
- Department of Haematology and Oncology, The Queen Elizabeth Hospital, Woodville South 5011, Adelaide, South Australia, Australia. .,School of Medicine, University of Adelaide, Adelaide, 5000, South Australia, Australia. .,SAHMRI Colorectal Node, Basil Hetzel Institute, Woodville South, Adelaide, South Australia, 5011, Australia.
| |
Collapse
|
21
|
Vatandoust S, McKay BP, McLeay W, Miliauskas J, Gordon L, Wesley JA, Kichenadasse G. Acrokeratosis paraneoplastica (Bazex syndrome) associated with metastatic cutaneous squamous cell carcinoma. Intern Med J 2016; 46:119-20. [PMID: 26813906 DOI: 10.1111/imj.12955] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2015] [Accepted: 05/20/2015] [Indexed: 11/28/2022]
Affiliation(s)
- S Vatandoust
- Flinders Medical Centre, Adelaide, South Australia, Australia. .,Flinders University, Adelaide, South Australia, Australia.
| | - B P McKay
- Flinders University, Adelaide, South Australia, Australia
| | - W McLeay
- Flinders Medical Centre, Adelaide, South Australia, Australia.,Flinders University, Adelaide, South Australia, Australia
| | - J Miliauskas
- SA Pathology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
| | - L Gordon
- Flinders Medical Centre, Adelaide, South Australia, Australia.,Flinders University, Adelaide, South Australia, Australia
| | - J A Wesley
- Dermatology Private Practice, Adelaide, South Australia, Australia
| | - G Kichenadasse
- Flinders Medical Centre, Adelaide, South Australia, Australia.,Flinders University, Adelaide, South Australia, Australia
| |
Collapse
|
22
|
Hu L, Kichenadasse G, Martin H, Roy A, Sukumaran S, Vatandoust S, Koczwara B, Karapetis CS. Pregnancy screening prior to chemotherapy administration. Intern Med J 2016; 46:1222-1224. [PMID: 27734613 DOI: 10.1111/imj.13214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Revised: 07/12/2016] [Accepted: 08/04/2016] [Indexed: 11/29/2022]
Abstract
A retrospective case notes review was performed to determine compliance with screening for undetected pregnancy prior to commencement of chemotherapy at Flinders Medical Centre. All female patients aged 18-55 who commenced chemotherapy between January and December 2014 were included. During the first 12 months, for women identified as having childbearing potential, pre-chemotherapy pregnancy screening was performed only in 40% of patients under 40 years and in 20.5% of the entire age range.
Collapse
Affiliation(s)
- L Hu
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| | - G Kichenadasse
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia.
| | - H Martin
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| | - A Roy
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| | - S Sukumaran
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| | - S Vatandoust
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| | - B Koczwara
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| | - C S Karapetis
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Adelaide, South Australia, Australia
| |
Collapse
|
23
|
Hsieh AHC, Kichenadasse G, Vatandoust S, Roy A, Sukumaran S, Karapetis CS, Martin H, Chong LC, Koczwara B. Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer. Intern Med J 2016; 46:1153-1159. [PMID: 27389059 DOI: 10.1111/imj.13169] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 06/27/2016] [Accepted: 06/27/2016] [Indexed: 11/29/2022]
Affiliation(s)
- A. H.-C. Hsieh
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
| | - G. Kichenadasse
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide South Australia Australia
| | - S. Vatandoust
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide South Australia Australia
| | - A. Roy
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide South Australia Australia
| | - S. Sukumaran
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
| | - C. S. Karapetis
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide South Australia Australia
| | - H. Martin
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
| | - L. C. Chong
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
| | - B. Koczwara
- Department of Medical Oncology; Flinders Medical Centre; Adelaide South Australia Australia
- Flinders Centre for Innovation in Cancer; Flinders University; Adelaide South Australia Australia
| |
Collapse
|
24
|
Vatandoust S, Price TJ, Ullah S, Roy AC, Beeke C, Young JP, Townsend A, Padbury R, Roder D, Karapetis CS. Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. Clin Colorectal Cancer 2016; 15:32-6. [PMID: 26341410 DOI: 10.1016/j.clcc.2015.07.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Accepted: 07/20/2015] [Indexed: 02/07/2023]
|
25
|
Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World J Gastroenterol 2015; 21:11767-11776. [PMID: 26557001 PMCID: PMC4631975 DOI: 10.3748/wjg.v21.i41.11767] [Citation(s) in RCA: 201] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2015] [Revised: 06/20/2015] [Accepted: 08/31/2015] [Indexed: 02/06/2023] Open
Abstract
Colorectal cancer (CRC) is a common malignancy worldwide. In CRC patients, metastases are the main cause of cancer-related mortality. In a group of metastatic CRC patients, the metastases are limited to a single site (solitary organ); the liver and lungs are the most commonly involved sites. When metastatic disease is limited to the liver and/or lungs, the resectability of the metastatic lesions will dictate the management approach and the outcome. Less commonly, the site of solitary organ CRC metastasis is the peritoneum. In these patients, cytoreduction followed by hyperthermic intraperitoneal chemotherapy may improve the outcome. Rarely, CRC involves other organs, such as the brain, bone, adrenals and spleen, as the only site of metastatic disease. There are limited data to guide clinical practice in these cases. Here, we have reviewed the disease characteristics, management approaches and prognosis based on the metastatic disease site in patients with CRC with metastases to a single organ.
Collapse
|
26
|
O'Callaghan ME, Kichenadasse G, Vatandoust S, Moretti K. Informed decision making about prostate cancer screening. Ann Intern Med 2015; 162:457. [PMID: 25775324 DOI: 10.7326/l15-5063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- Michael E. O'Callaghan
- From Repatriation General Hospital, Flinders University, and The University of Adelaide, Adelaide, South Australia, Australia
| | - Ganessan Kichenadasse
- From Repatriation General Hospital, Flinders University, and The University of Adelaide, Adelaide, South Australia, Australia
| | - Sina Vatandoust
- From Repatriation General Hospital, Flinders University, and The University of Adelaide, Adelaide, South Australia, Australia
| | - Kim Moretti
- From Repatriation General Hospital, Flinders University, and The University of Adelaide, Adelaide, South Australia, Australia
| |
Collapse
|
27
|
Singhal N, Vatandoust S, Brown MP. Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity. Cancer Chemother Pharmacol 2014; 75:325-31. [PMID: 25502181 DOI: 10.1007/s00280-014-2644-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 11/30/2014] [Indexed: 10/24/2022]
Abstract
INTRODUCTION Lung cancer is one of the most common malignancies worldwide. Non-small cell lung cancer (NSCLC) comprises the majority of the cases of lung cancer. Previous studies have demonstrated a role for both the estrogen pathway and mammalian target of rapamycin (mTOR) in NSCLC. METHODS This single-arm phase 2 study was designed to assess the safety and efficacy of combination treatment with aromatase inhibitor—letrozole—and mTOR inhibitor—everolimus—in the treatment of patients with advanced (unresectable stage III or stage IV) NSCLC who had failed at least one line of platinum-based chemotherapy. RESULTS The study was closed after enrolling five patients due to safety concerns. Of the five patients treated with the study combination, two patients developed grade 5 pulmonary toxicity and another patient developed reversible grade 4 pulmonary toxicity. CONCLUSIONS There is a probable causal relationship between the study medication and the reported serious adverse events. In the absence of additional clinical data in lung cancer patients, we recommend that extreme caution be exercised in the use of combined letrozole and everolimus regimens in patients with advanced lung cancers, active pulmonary pathologies, or both.
Collapse
Affiliation(s)
- Nimit Singhal
- Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia,
| | | | | |
Collapse
|
28
|
Padman S, Lee J, Kumar R, Slee M, Hakendorf P, Richards A, Koczwara B, Kichenadasse G, Sukumaran S, Roy A, Vatandoust S, Karapetis CS. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Support Care Cancer 2014; 23:861-9. [PMID: 25223350 DOI: 10.1007/s00520-014-2423-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2014] [Accepted: 08/25/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVES Oxaliplatin accumulates in dorsal root ganglia, causing an axonal neuronopathy. Symptoms include numbness, pain and gait disturbance which may persist and impact on quality of life (QOL). Despite widespread use of this drug, its late effects and patient satisfaction outcomes have not been widely reported. Furthermore, there has been limited qualitative research published in this area. The objectives of this study were to establish the incidence and clinical impact of chronic peripheral neuropathy. METHODS We conducted a cross-sectional observational study of patients who started oxaliplatin treatment at least 2 years prior to study commencement. Patients were assessed in three ways: clinical assessment encompassing neurological examination and nerve conduction studies to calculate a total neuropathy score (TNS); self-reported assessment via validated questionnaires; and assessment by recorded interview. The clinical and questionnaire-based assessments were analysed quantitatively and the interview data used for qualitative assessment. RESULTS Twenty-five patients consented to participate. The mean starting dose of oxaliplatin given was 92 mg/m(2). The cumulative dose received ranged from 375 to 2,400 mg, with a mean cumulative dose of 1,515 mg. Oxaliplatin was ceased due to neuropathy in six patients (24 %), after a mean of 9 cycles of treatment. Modified TNS ranged from 1 to 15 with a mean of 9.5. There was a statistically significant correlation between cumulative oxaliplatin dose and TNS. Quality of life and functional impact questionnaires showed mildly lower physical quality of life, higher pain scores and functional impairment secondary to sensory deficit. Qualitative analysis demonstrated variable bio-psycho-social effects of chronic neuropathy but, importantly, highlighted that many patients felt they had been insufficiently warned of the risk of neuropathy. Despite this, the majority was satisfied with their decision to receive the drug. CONCLUSION Many patients objectively demonstrated mild to moderate oxaliplatin neuropathy >2 years post-treatment. The majority of patients did not recall being warned of the risks of chronic peripheral neuropathy. Many of those who recall being warned did not feel sufficient emphasis was placed on the issue. Despite a varying burden of neuropathic symptoms, the majority of patients were highly satisfied with their decision to receive oxaliplatin.
Collapse
Affiliation(s)
- Sunita Padman
- Flinders Medical Centre, Bedford Park, South Australia, Australia,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Vatandoust S, O'callaghan M, Kopsaftis T, Walsh S, Borg M, Kichenadasse G. Prostate Cancer (Pca) in Elderly Men – Findings from South Australian Prostate Cancer Clinical Outcome Collaborative (Sa-Pccoc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Vatandoust S, Price TJ, Padbury R, Roder D, Beeke C, Roy A, Townsend AR, Karapetis CS. Patterns of care and outcomes for young patients (age < 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e17584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Sina Vatandoust
- Flinders Centre for Innovation in Cancer, Adelaide, Australia
| | - Timothy Jay Price
- The Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia
| | - Rob Padbury
- Department of Surgery, Flinders Medical Centre, Adelaide, Australia
| | - David Roder
- Cancer Epidemiology, Division of Health Sciences, Sansom Institute for Health Research, Adelaide, Australia
| | - Carol Beeke
- Department of Surgery, Flinders Medical Centre, Adelaide, Australia
| | - Amitesh Roy
- Flinders Medical Centre, Adelaide, Australia
| | | | - Christos Stelios Karapetis
- Flinders Medical Centre and Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia
| |
Collapse
|
31
|
Vatandoust S, Singhal N, Brown MP. Phase 2 study evaluating efficacy and safety of everolimus with letrozole in advanced (unresectable or metastatic) non-small cell lung cancer (NSCLC) after failure of platinum-based treatment: A preliminary analysis of toxicity. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Butt SR, Vatandoust S, Kleinig T, Adams J, Basu S, Otto G, Joshi R. Anti-Ri antibody-associated paraneoplastic brainstem encephalitis successfully treated after treating the underlying malignancy with letrozole. Intern Med J 2013; 43:605-6. [PMID: 23668275 DOI: 10.1111/imj.12123] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Accepted: 12/14/2012] [Indexed: 12/01/2022]
Affiliation(s)
- S. -R. Butt
- Department of Medical Oncology; Lyell McEwin Hospital; Adelaide South Australia Australia
| | - S. Vatandoust
- Department of Medical Oncology; Lyell McEwin Hospital; Adelaide South Australia Australia
| | - T. Kleinig
- Department of Stroke and Neurology; Lyell McEwin Hospital; Adelaide South Australia Australia
| | - J. Adams
- Department of Medical Oncology; Lyell McEwin Hospital; Adelaide South Australia Australia
| | - S. Basu
- Department of Stroke and Neurology; Lyell McEwin Hospital; Adelaide South Australia Australia
| | - G. Otto
- Department of Surgery; Lyell McEwin Hospital; Adelaide South Australia Australia
| | - R. Joshi
- Department of Medical Oncology; Lyell McEwin Hospital; Adelaide South Australia Australia
| |
Collapse
|
33
|
Vatandoust S, Joshi R, Broadbridge V, Pittman KB, Adams J, Singhal N, Colbeck M, Yeend S, Price TJ. Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e19513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19513 Background: Available data suggest that the OX-induced neuropathy is usually reversible and a minority of pts will have persistent severe (grade 3) side effects (24.1% any grade and 0.7% grade 3 at 18 months follow up from MOSAIC trial). We have explored the frequency of persistent peripheral neuropathy in pts who received OX for colorectal cancer at 2 local centres in South Australia. Methods: Pts who completed treatment with OX for colorectal cancer at least 20 months prior to entering the study were eligible and were sent consent and questionnaire. Neuropathy questions were adapted from the FACT/GOG-Ntx (V.4) questionnaire. No pts received Calcium and Magnesium with OX. Statistical tests used to analyze the data were t-test and chi- square. Results: Of the 56 eligible pts, 27 consented to enrol in the study. Median age was 66 yrs. 19 were stage 3, 8 stage 4. Mean total OX dose was 712.1 mg/m2 (range: 170 - 1200 mg/m2); mean number of OX cycles was 8.2 (range 2 - 13), median time between last dose of OX and completing the questionnaire was 37 months (range 20 - 93). 7 pts (25.9%) had a history of diabetes mellitus and 7 had significant alcohol intake. No pts had neuropathic symptoms prior to treatment with OX. 25 pts (92.7%) experienced neuropathic symptoms during their treatment, 11 had grade 2, and 2 had grade 3 symptoms (limiting self care activities of daily living). At the time of completing the questionnaire, 17 pts (63%) were still symptomatic with 9 pts (33.3%) having grade 2 and 3 pts (11.1%) having grade 3 neuropathic symptoms. In the cohort of pts with persistent grade 2 symptoms, 3 pts had walking difficulty and 2 pts could not drive safely due to side effects. Persistent grade 2/3 symptoms were more common in pts who received total OX doses of 722 mg/m2 or more (p < 0.05). Conclusions: Our observation indicates that a majority of pts will have persistent neuropathy more than 20 months after completing treatment with OX and a significant proportion will still have grade 2/3 symptoms. Higher total OX dose might be one of the risk factors in this group. These results should be further prospectively evaluated in a larger population as these long term side effects may affect pts’ daily activities and safety.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Susan Yeend
- The Queen Elizabeth Hospital, Adelaide, Australia
| | | |
Collapse
|
34
|
Mohyeddin Bonab M, Alimoghaddam K, Vatandoust S, Forouzia F, Jahani M, Ghavamzadeh A. Are HLA antigens a risk factor for acute GVHD in thalassemic patients receiving HLA-identical stem cell transplantation? Transplant Proc 2005; 36:3190-3. [PMID: 15686726 DOI: 10.1016/j.transproceed.2004.10.088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
We retrospectively evaluated the association between risk factors and acute graft-versus-host disease (aGVHD) among 182 beta thalassemia patients who received 73 peripheral blood stem cell (PBSC) or 109 bone marrow transplants from HLA-identical siblings between 1991 and 2003. The relationship between the severity of aGVHD was examined for the following factors: HLA antigens, age, sex, ABO mismatch, sex mismatch (between recipient and donor), thalassemia class, graft source, transplant cell dose, CD3+ cell dose, conditioning regimen, GVHD prophylaxis, neutrophil engraftment duration, and blood product transfusions using univariate and multivariate analyses. Overall 61 (34%) patients developed clinical grade III or grade IV aGVHD. Univariate analysis confirmed an increased risk of severe aGVHD, which was associated with HLA-A11, HLA-A26, and PBSCT (P=.04, .03, and .03, respectively). The risk of aGVHD was reduced in the presence of HLA-A3 (P=.03). Multivariate analysis confirmed the increased risk of aGVHD associated with HLA-A11 (P=.04), HLA-A26 (P=.01), and a short-period neutrophil recovery (P=.009). In this study HLA-A11, HLA-A26, PBSCT, and a short neutrophil engraftment period were probable risk factors and HLA-A3 a probable protective factor associated with severe aGVHD. These data may provide useful guidelines to choose strategies for treatment and prevention.
Collapse
Affiliation(s)
- M Mohyeddin Bonab
- Heamatology, Oncology, and BMT Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | |
Collapse
|